专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013003586A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE 审中-公开
标题翻译：喹唑啉作为治疗化合物及相关使用方法
公开(公告)号：WO2013003586A1
公开(公告)日：2013-01-03
申请号：PCT/US2012/044636
申请日：2012-06-28
申请人： OTSUKA PHARMACEUTICAL CO., LTD. , SUZUKI, Masaki , KONDO, Kazumi , KURIMURA, Muneaki , VALLURU, Krishna Reddy , TAKAHASHI, Akira , KURODA, Takeshi , TAKAHASHI, Haruka , FUKUSHIMA, Tae , MIYAMURA, Shin , GHOSH, Indranath , DOGRA, Abhishek , HARRIMAN, Geraldine , ELDER, Amy , SHIMIZU, Satoshi , HODGETTS, Kevin, J. , NEWCOM, Jason, S.
发明人： SUZUKI, Masaki , KONDO, Kazumi , KURIMURA, Muneaki , VALLURU, Krishna Reddy , TAKAHASHI, Akira , KURODA, Takeshi , TAKAHASHI, Haruka , FUKUSHIMA, Tae , MIYAMURA, Shin , GHOSH, Indranath , DOGRA, Abhishek , HARRIMAN, Geraldine , ELDER, Amy , SHIMIZU, Satoshi , HODGETTS, Kevin, J. , NEWCOM, Jason, S.
IPC分类号： C07D487/04
CPC分类号： C07D405/14 , A61K31/517 , A61K45/06 , C07D401/04 , C07D401/14 , C07D403/04 , C07D413/14 , C07D417/14 , C07D487/04
摘要： Methods of treating disorders using compounds (I) that modulate stri-atal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit. Formula (I).
摘要翻译：本文描述了使用调节富含丝氨酸的酪氨酸磷酸酶（STEP）的化合物（I）治疗病症的方法。示例性的疾病包括精神分裂症和认知缺陷。式（I）。

2. 发明申请

WO2011082337A1 THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE 审中-公开
标题翻译：治疗化合物及其相关使用方法
公开(公告)号：WO2011082337A1
公开(公告)日：2011-07-07
申请号：PCT/US2010/062555
申请日：2010-12-30
申请人： GALENEA CORP. , OTSUKA PHARMACEUTICAL CO., LTD. , SUZUKI, Masaki , KONDO, Kazumi , KURIMURA, Muneaki , VALLURU, Krishna, Reddy , TAKAHASHI, Akira , KURODA, Takeshi , TAKAHASHI, Haruka , FUKUSHIMA, Tae , MIYAMURA, Shin , GHOSH, Indranath , DOGRA, Abhishek , HARRIMAN, Geraldine , ELDER, Amy , SHIMIZU, Satoshi , HODGETTS, Kevin, J. , NEWCOM, Jason, S.
发明人： SUZUKI, Masaki , KONDO, Kazumi , KURIMURA, Muneaki , VALLURU, Krishna, Reddy , TAKAHASHI, Akira , KURODA, Takeshi , TAKAHASHI, Haruka , FUKUSHIMA, Tae , MIYAMURA, Shin , GHOSH, Indranath , DOGRA, Abhishek , HARRIMAN, Geraldine , ELDER, Amy , SHIMIZU, Satoshi , HODGETTS, Kevin, J. , NEWCOM, Jason, S.
IPC分类号： A61K31/52
CPC分类号： C07D401/04 , A61K31/517 , A61K45/06 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D495/04
摘要： Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.
摘要翻译：本文描述了使用调节纹状体富含酪氨酸磷酸酶的化合物（STEP）治疗病症的方法。示例性疾病包括精神分裂症和认知缺陷。

3. 发明申请

WO2010137738A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS 审中-公开
标题翻译：用于治疗压力相关条件的杂环化合物
公开(公告)号：WO2010137738A1
公开(公告)日：2010-12-02
申请号：PCT/JP2010/059405
申请日：2010-05-27
申请人： OTSUKA PHARMACEUTICAL CO., LTD. , TAKAHASHI, Akira , SUZUKI, Masaki , NAKAMURA, Yuichi , SAKURAI, Yohji
发明人： TAKAHASHI, Akira , SUZUKI, Masaki , NAKAMURA, Yuichi , SAKURAI, Yohji
IPC分类号： A61K31/519 , C07D471/04 , A61P25/22 , A61P25/24
CPC分类号： C07D471/04 , A61K31/519 , C07D491/048 , C07D491/056 , C07D495/04 , C07D519/00
摘要： The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R 1 and R 2 , each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R 3 represents a lower alkynyl group or the like; R 4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.
摘要翻译：本发明提供了一种新的杂环化合物。由通式（1）表示的杂环化合物，其中，R 1和R 2各自独立地表示氢; 在苯环和/或低级烷基上可以具有选自低级烷基等的取代基的苯基低级烷基; 或环C 3 -C 8烷基低级烷基; 或类似物; R3表示低级炔基等; R4表示可以具有选自可以具有例如卤素或选自吡啶基等的杂环基的1,3,4-恶二唑基的取代基的苯基; 杂环基可以具有至少一个选自低级烷氧基等的取代基或其盐。

4. 发明申请

WO2018221667A1 PYRIMIDINE COMPOUND 审中-公开
公开(公告)号：WO2018221667A1
公开(公告)日：2018-12-06
申请号：PCT/JP2018/020997
申请日：2018-05-31
申请人： OTSUKA PHARMACEUTICAL CO., LTD.
发明人： SHINOHARA, Tomoichi , IWATA, Shin , ARAI, Kenta , ITO, Nobuaki , SUZUKI, Masaki
IPC分类号： C07D239/22 , C07D239/54 , A61K31/506 , A61P25/08
摘要： The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof: [in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

5. 发明申请

WO2005088977A1 MOVING IMAGE CODING APPARATUS, MOVING IMAGE DECODING APPARATUS, CONTROL METHOD THEREFOR, COMPUTER PROGRAM, AND COMPUTER-READABLE STORAGE MEDIUM 审中-公开
标题翻译：移动图像编码装置，移动图像解码装置，其控制方法，计算机程序和计算机可读存储介质
公开(公告)号：WO2005088977A1
公开(公告)日：2005-09-22
申请号：PCT/JP2005/004851
申请日：2005-03-11
申请人： CANON KABUSHIKI KAISHA , KAJIWARA, Hiroshi , MAEDA, Mitsuru , SUZUKI, Masaki , KISHI, Hiroki
发明人： KAJIWARA, Hiroshi , MAEDA, Mitsuru , SUZUKI, Masaki , KISHI, Hiroki
IPC分类号： H04N7/30
CPC分类号： H04N19/64 , H04N19/169 , H04N19/17 , H04N19/184 , H04N19/46 , H04N19/61 , H04N19/63
摘要： This invention provides a technique of preventing errors from being gradually accumulated on the decoding side, while maintaining high scalability, even when a technique for transformation to subbands as a plurality of frequency components, like discrete wavelet transformation, is used for moving image coding. The image data of one input frame is decomposed into a plurality of subbands having different frequency components by a discrete wavelet transformation unit (101). A lower bitplane coding unit (109) codes, for each bitplane, predetermined lower bits of each coefficient data of a subband LL and the coefficient data of subbands other than the subband LL. The data of the upper bits of the subband LL is stored in a frame memory (105). A motion vector detection unit (107) detects a predicted value and motion vector on the basis of the decoded data of the subband LL in a preceding frame. A subtracter (103) obtains the difference between the detected predicted value and the current frame. A coefficient coding unit (104) codes the obtained difference. A motion vector coding unit (108) codes the motion vector. A multiplexing unit (111) multiplexes the code data obtained by the coding units (104, 108, 109).
摘要翻译：本发明提供了一种防止错误逐渐积累在解码侧的技术，同时保持高的可扩展性，即使将用于变换为多个频率分量的子带（如离散小波变换）的变换技术用于运动图像编码也是如此。通过离散小波变换单元（101）将一个输入帧的图像数据分解成具有不同频率分量的多个子带。低位平面编码单元（109）针对每个位平面编码子带LL的每个系数数据的预定低位和子带LL以外的子带的系数数据。子带LL的高位的数据被存储在帧存储器（105）中。运动矢量检测单元（107）根据前一帧中的子带LL的解码数据来检测预测值和运动矢量。减法器（103）获得检测到的预测值与当前帧之间的差。系数编码单元（104）对获得的差值进行编码。运动矢量编码单元（108）对运动矢量进行编码。复用单元（111）对由编码单元（104,108,109）获得的编码数据进行复用。

6. 发明申请

WO2007077005A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS 审中-公开
标题翻译： 3,5-取代的哌啶化合物作为RININ抑制剂
公开(公告)号：WO2007077005A1
公开(公告)日：2007-07-12
申请号：PCT/EP2006/012581
申请日：2006-12-28
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , EHARA, Takeru , GROSCHE, Philipp , IRIE, Osamu , IWAKI, Yuki , KANAZAWA, Takanori , KAWAKAMI, Shimpei , KONISHI, Kazuhide , MOGI, Muneto , SUZUKI, Masaki , YOKOKAWA, Fumiaki
发明人： EHARA, Takeru , GROSCHE, Philipp , IRIE, Osamu , IWAKI, Yuki , KANAZAWA, Takanori , KAWAKAMI, Shimpei , KONISHI, Kazuhide , MOGI, Muneto , SUZUKI, Masaki , YOKOKAWA, Fumiaki
IPC分类号： C07D211/60 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D471/04 , A61K31/445 , A61K31/4525 , A61K31/453 , A61K31/4535 , A61K31/454 , A61K31/4545
CPC分类号： C07D401/12 , C07D211/60 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D471/04
摘要： The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3, 5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula (I'), wherein R1 , R2, T, R3 and R4 are as defined in the specification.
摘要翻译：本发明涉及3,5-取代的哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于肾素活性的疾病（=病症）; 使用该类化合物制备用于治疗依赖于肾素活性的疾病的药物制剂; 使用该类化合物治疗依赖于肾素活性的疾病; 包括3,5-取代的哌啶化合物的药物制剂和/或治疗方法，包括给予3,5-取代的哌啶化合物，制备3,5-取代的哌啶化合物的方法和新的中间体和部分其合成步骤。优选的化合物（其也可以盐形式存在）具有式（I'），其中R 1，R 2，T，R 3和R 4如说明书中所定义。

7. 发明申请

WO2012014383A1 A METHOD AND A SYSTEM FOR TREATING HAZARDOUS MATERIALS THAT HAVE BEEN GENERATED IN A FOUNDRY LINE 审中-公开
标题翻译：用于处理在基线中产生的危险材料的方法和系统
公开(公告)号：WO2012014383A1
公开(公告)日：2012-02-02
申请号：PCT/JP2011/003836
申请日：2011-07-05
申请人： Sintokogio, Ltd. , SUZUKI, Masaki , AMANO, Hiroyuki
发明人： SUZUKI, Masaki , AMANO, Hiroyuki
IPC分类号： B22C5/10
CPC分类号： B22C5/10 , B22C25/00
摘要： A method and a system for treating hazardous materials by insolubilizing the hazardous materials, such as heavy metals and halogen, that are contained in collected dust are provided. Only a small facility must be added to a foundry line. The foundry line reuses molding sand by performing the steps of shaking out a casting (14), reclaiming the molding sand (11), and mulling the sand (10). The collected dust that has been generated in the foundry line is transported to the step of mulling the sand to mull the molding sand with the dust and an insolubilizing agent. Thus the hazardous materials are insolubilized. Since no facility for insolubilizing the hazardous materials is required, the cost for facilities can be reduced. Further, if the treated sand is reused for a raw material for cement or a roadbed, no hazardous materials elute.
摘要翻译：提供了一种通过使收集的灰尘中含有的重金属和卤素等有害物质不溶解来处理有害物质的方法和系统。只有一个小的设施必须添加到铸造生产线。铸造线通过执行摇动铸件（14），回收型砂（11）和研磨砂（10）的步骤重新使用型砂。在铸造线中产生的收集的灰尘被运送到用砂磨机和不溶解剂研磨砂的步骤。因此有害物质不溶解。由于不需要使危险材料不溶解的设施，因此可以降低设施成本。此外，如果经处理的砂被重新用于水泥或路基的原料，则不会有危险的物质被洗脱。

8. 发明申请

WO2006069788A1 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2006069788A1
公开(公告)日：2006-07-06
申请号：PCT/EP2005/014102
申请日：2005-12-28
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BREITENSTEIN, Werner , EHARA, Takeru , EHRHARDT, Claus , GROSCHE, Philipp , HITOMI, Yuko , IWAKI, Yuki , KANAZAWA, Takanori , KONISHI, Kazuhide , MAIBAUM, Juergen, Klaus , MASUYA, Keiichi , NIHONYANAGI, Atsuko , OSTERMANN, Nils , SUZUKI, Masaki , TOYAO, Atsushi , YOKOKAWA, Fumiaki
发明人： BREITENSTEIN, Werner , EHARA, Takeru , EHRHARDT, Claus , GROSCHE, Philipp , HITOMI, Yuko , IWAKI, Yuki , KANAZAWA, Takanori , KONISHI, Kazuhide , MAIBAUM, Juergen, Klaus , MASUYA, Keiichi , NIHONYANAGI, Atsuko , OSTERMANN, Nils , SUZUKI, Masaki , TOYAO, Atsushi , YOKOKAWA, Fumiaki
IPC分类号： C07D401/10 , C07D401/12 , C07D413/12 , C07D413/04 , C07D409/12 , C07D405/12 , C07D409/10 , C07D401/14 , C07D417/12 , C07D413/14 , C07D471/04 , A61K31/4545 , A61P9/00
CPC分类号： C07D471/04 , C07D211/60 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/10 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12
摘要： 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.
摘要翻译： 3,4-取代的哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于肾素活性的疾病（=病症）; 使用该类化合物制备用于治疗依赖于肾素活性的疾病的药物制剂; 使用该类化合物治疗依赖于肾素活性的疾病; 包含3,4-取代的哌啶化合物的药物制剂和/或包括给药3,4代哌啶化合物的方法，制备3,4-取代的哌啶化合物的方法和新的中间体和部分步骤因为它们的合成被公开。 3,4-二取代的哌啶化合物具有式（I），其中符号具有说明书中定义的含义。

9. 发明申请

WO2006094763A1 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2006094763A1
公开(公告)日：2006-09-14
申请号：PCT/EP2006/002083
申请日：2006-03-07
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , MASUYA, Keiichi , YOKOKAWA, Fumiaki , IRIE, Osamu , NIHONYANAGI, Atsuko , TOYAO, Atsushi , EHARA, Takeru , KONISHI, Kazuhide , KANAZAWA, Takanori , SUZUKI, Masaki
发明人： MASUYA, Keiichi , YOKOKAWA, Fumiaki , IRIE, Osamu , NIHONYANAGI, Atsuko , TOYAO, Atsushi , EHARA, Takeru , KONISHI, Kazuhide , KANAZAWA, Takanori , SUZUKI, Masaki
IPC分类号： C07D211/60 , C07D401/12 , C07D413/12 , A61K31/4545 , A61P9/00
CPC分类号： C07D401/12 , C07D211/60 , C07D413/12
摘要： 3,4,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4,5-substituted piperidine compound, a method for the manufacture of a 3,4,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds are of the formula (I), wherein the substitutents are as defined in the specification.
摘要翻译： 3,4,5-取代的哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于肾素活性的疾病（=病症）; 使用该类化合物制备用于治疗依赖于肾素活性的疾病的药物制剂; 使用该类化合物治疗依赖于肾素活性的疾病; 包含3,4,5-取代的哌啶化合物的药物制剂和/或治疗方法，包括给予3,4,5-取代的哌啶化合物，制备3,4,5-取代哌啶化合物的方法，以及其合成的新型中间体和部分步骤。化合物是式（I），其中取代基如说明书中所定义。

10. 发明申请

WO2006057433A1 MOTOR VEHICLE AND CONTROL METHOD OF MOTOR VEHICLE 审中-公开
标题翻译：电动车辆的电机和控制方法
公开(公告)号：WO2006057433A1
公开(公告)日：2006-06-01
申请号：PCT/JP2005/022040
申请日：2005-11-24
申请人： TOYOTA JIDOSHA KABUSHIKI KAISHA , SUZUKI, Masaki
发明人： SUZUKI, Masaki
IPC分类号： F02D41/06 , F02D29/02 , B60K6/04 , B60H1/00
CPC分类号： B60W20/15 , B60H1/004 , B60H1/00764 , B60K6/445 , B60W10/06 , B60W10/08 , B60W10/30 , B60W20/00 , B60W2710/086 , F02D29/02 , F02D41/06 , F02N11/084 , F02N2200/0806 , Y02T10/48 , Y02T10/6239 , Y02T10/6286
摘要： When a vehicle power demand P* is less than a threshold value Pref, which is set to or around a lower limit of a relatively efficient drive range of an engine (step S120) and when an engine drive demand EG* is set ON because of requirement for heating by an air conditioning system (step S150), the drive control of the invention sets the threshold value Pref to an engine power demand Pe* (step S160) and sets a higher level S2 than a standard level S1 to a maximum SOC (state of charge) of a battery (step S170). This drive control starts load operation of the engine with charge of the battery. The load operation of the engine desirably improves the fuel consumption of the vehicle, compared with independent operation of the engine.
摘要翻译：当车辆功率需求P *小于设定在发动机的相对有效的驱动范围的下限（步骤S120）的周围的阈值Pref，以及当发动机驱动要求EG *设定为ON时，由于通过空调系统进行加热的要求（步骤S150），本发明的驱动控制将阈值Pref设定为发动机功率需求Pe *（步骤S160），将高于标准电平S1的高电平S2设定为最大SOC （充电状态）（步骤S170）。该驱动控制开始负载电池的负载运行。与发动机的独立操作相比，发动机的负载操作期望地改善了车辆的燃料消耗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式